BMS's Zeposia Shines in Ulcerative Colitis Phase III Study
Success Augurs Well For S1P Drug Class in UC
BMS’s S1P receptor modulator met endpoints in a Phase III trial treating patients with moderate to severe ulcerative colitis, boosting the drug class’s prospects in that condition.
